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Maxim Norkin, John R. WingardDespite significant progress in prevention and
treatment of cytomegalovirus (CMV) infection in allo-
geneic hematopoietic cell transplant (HCT) recipi-
ents, CMV reactivation occurs in approximately 60%
to 70% of seropositive allogeneic HCT recipients
and remains a risk factor for transplantation-related
morbidity and mortality. Over the years, the incidence
of CMV disease in HCT recipients has declined dra-
matically as a result of efforts to prevent primary infec-
tion in seronegative patients and use of prophylactic or
pre-emptive antiviral therapy in seropositive patients.
However, current antiviral therapy is associated with
significant toxicity. Even though CMV disease is rare
today, CMV seropositivity is associated with inferior
survival in various subsets of patients, especially in
recipients of T cell depleted grafts [1]. It has been
suggested that CMV exerts immunomodulatory
effects in yet unclear ways, indirectly influencing
graft-versus-host disease (GVHD) and bacterial and
fungal infections. Clearly, novel approaches to reduce
CMV-associated morbidity and mortality in HSCT
recipients are needed. Several new approaches are
being evaluated: new and less toxic antiviral drugs,
vaccines, and immune cellular therapies.
In this issue of BBMT, Lum et al. [2] describe pre-
clinical studies of a novel cellular approach against
CMV infection, which they hope to test as adoptive
immunotherapy in the future. They have developed
ex vivo expanded activated cytotoxic T cells (ATC)
armed by bispecific polyclonal anti-CD3  anti-
CMV Abs (CMVBi). The idea of adoptive immuno-
therapy with cytotoxic T lymphocytes to control viral
replication is not new. Decades ago, it was found that
natural killer (NK) and cytotoxic T cell mediated cel-
lular immunity is crucial in suppressing CMV replica-
tion and preventing CMV disease after HCT [3,4].
Riddel et al. [5] have demonstrated that adoptive trans-
fer of cytotoxic CD81 T cells from the donors into
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from CMV-related complications, but adequate num-
bers of CMV-specific CD41 cells were important for
persistence of CMV immunity.
Lum et al. [2] demonstrate that the ex vivo
expanded ATC armed by CMVBi have potent anti-
CMV specific cytotoxicity against CMV infected
fibroblasts while sparing uninfected cellular targets.
They further demonstrate that the effect was not
due to Ab-dependent cell-mediated cytotoxicity or
complement-mediated cytotoxicity, was not restricted
by need for HLA compatibility with infected target
cells, was not affected by irradiation, and did not
seem to induce substantial alloreactive responses to
HLA disparate targets. It is important to mention
that CMVBi armed with ATC were highly active at ef-
fector:target ratio of as low as 1:1, suggesting that low
numbers of ATC might be sufficient to elicit an effec-
tive anti-CMV activity, which could minimize side ef-
fects associated with infusion of alloreactive cytotoxic
cells in high amounts.
There are several potential strengths and limitations
for this approach. One strength is the use of polyclonal
Abs targeting multiple CMV epitopes increases the
chance that themultipleCMVgenotypeswill be suscep-
tible and reduces the well known ability of CMV to
evade cellular immune responses. One concern is that
the CMVBi was constructed by using Cytogam (CSL
Behring, King of Prussia, PA), a polyclonal human im-
munoglobulin preparation, which contains multiple
non-CMV directed Abs mixed among the CMV Abs.
It raises the theoretical concern that a significant frac-
tion of armed bispecific Abs could result in unpredict-
able autoimmune responses. In addition, Cytogam
preparation is subject to significant variability from
batch to batch, which could be associated with variable
efficacy and toxicity.
Notwithstanding, this approach seems quite
promising. The authors suggest that lower costs, pos-
sibly less toxicity, and the lack of need of HLA match-
ing with the recipient are potential advantages over
other antiviral engineered Ab and other T cell adoptive
immunotherapy approaches. However, these will need
to stand the rigors of clinical studies to know if these
hopes are realized. Such studies will need to establish
dose, dose schedule, and durability of CMV protec-
tion. In addition to CMV disease protection, such
studies will need to demonstrate safety without an un-
intended increase in GVHD or development of
autoimmune sequealae.
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also seem promising. Because NK-cell mediated anti-
viral response plays a significant role in CMV clear-
ance [6], expansion of ‘‘CMV-armed NK-cells’’
could be considered for adoptive immunotherapy
which, like the Lum approach, could minimize the
risk of GVHD. Other competing strategies are also
being evaluated. A DNA vaccine ASP0113 (Trans-
Vax) against CMV has already undergone testing in
phase 1 and 2 studies and was shown to be safe, im-
munogenic, and effective with impressive reduction
in the CMV viremia episodes 1 year after transplan-
tation in CMV seropositive HCT recipients as com-
pared to placebo. The vaccine was well-tolerated and
the incidence of common adverse events after HCT
including GVHD or secondary infections was not
significantly increased [7]. A phase 3 study will be ini-
tiated in the near future. There is also progress in
drug therapy for CMV infection in HSCT recipients
as well. A new orally bioavailable lipid conjugate of
cidofovir (CMX001) is currently being investigated
for the prevention and treatment of double-stranded
DNA viruses, including CMV. A recently completed
randomized phase 2 trial confirmed acceptable safety,
tolerability, and antiviral activity of CMX001 in
CMV seropositive HSCT recipients [8]. To be adop-
ted in the clinic, CMVBi will need to show compara-
ble or better efficacy and safety compared with these
strategies.
In conclusion, Lum et al. [2] present intriguing
preclinical data utilizing CMVBi armed with ATC
against CMV infected fibroblasts. Results described
by the authors clearly warrant further investigation,
but feasibility of this approach needs to be confirmed
in phase 1 and 2 studies.ACKNOWLEDGMENT
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